Patient characteristics.
| N | % | |
|---|---|---|
| Age, years | ||
| Median (range) | 34 (22–79) | |
| Age≥65 | 4 | 20 |
| Sex | ||
| Male | 13 | 65 |
| Female | 7 | 35 |
| Histology | ||
| Nodular sclerosis | 9 | 45 |
| Mixed cellularity | 6 | 30 |
| Subtype indeterminate | 5 | 25 |
| ECOG performance status | ||
| 0 | 12 | 60 |
| 1 | 5 | 25 |
| 2 | 3 | 15 |
| EBV in-situ hybridization | ||
| Negative | 6 | 30 |
| Positive | 7 | 35 |
| Unknown | 7 | 35 |
| B symptom | ||
| No | 18 | 90 |
| Yes | 2 | 10 |
| Stage | ||
| I | 1 | 5 |
| II | 4 | 20 |
| III | 6 | 30 |
| IV | 9 | 45 |
| Extranodal involvement | ||
| Lung | 9 | 45 |
| Bone | 7 | 35 |
| Liver | 2 | 10 |
| Prior ASCT | 7 | 35 |
| Prior radiotherapy, No. | 4 | 20 |
| Prior brentuximab vedotin, No. | 12 | 60 |
| Prior chemotherapies, No. | ||
| 1–3 | 14 | 70 |
| ≥4 | 6 | 30 |
Abbreviations: ASCT, autologous hematopoietic stem cell transplantation; EBV, Epstein-Barr virus; ECOG, eastern cooperative oncology group.
Blood Res 2020;55:85~90 https://doi.org/10.5045/br.2020.2020014
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd